3rd Annual West Cancer Center Oncology Conference: Insights
Webcast
Webcast

3rd Annual West Cancer Center Oncology Conference: Insights

WEST Oncology Conference – at Graceland®

Not a member of My prIME? Join now for instant access.

If you missed the live WEST Oncology Conference event, or if you need reminding of the practice-changing presentation and discussions, please check out the updates in women’s cancers, genitourinary malignancies, disparities in cancer care, gastrointestinal cancers, head and neck cancers, and lung cancer.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Dec 11, 2017

Expiration Date

Dec 11, 2018

Introduction

West Cancer Center 2016-2017
Lee Schwartzberg, MD, FACP

Women’s Cancer

Novel targeted therapies and immunotherapy in ovarian cancer
Robert L. Coleman, MD, FACOG, FACS

Emerging targets in breast cancer – TNBC
Andrew Seidman, MD

Evolving concepts in breast surgery in multidisciplinary care
Tina Hieken, MD, FACS

Hormone receptors: A broader understanding (CK, AR, ESR1)
Anthony Elias, MD

Updates in HER2-positive breast cancer
Andrew Seidman, MD

Genitourinary Malignancies

Molecular approaches to genitourinary (GU) oncology and beyond
Petros Grivas, MD, PhD

Immunotherapy in GU oncology
Daniel P. Petrylak, MD

Eradicating turfism in GU oncology
Amit Gupta, MD, MPH

Keynote Address

Drive to eliminate disparities in cancer care delivery
Edith P. Mitchell, MD, FACP

Gastrointestinal Cancers

Review of gastrointestinal (GI) carcinoid tumors: Latest therapies
Arvind Dasari, MD

Emerging concepts in the multidisciplinary management of rectal cancer
Thomas J. George, Jr, MD, FACP 

HIPEC: An exploration of the data
Jeremiah Deneve, DO, FACS

Front-line therapy and beyond for metastatic colorectal cancer: Novel targets
Wells Messersmith, MD, FACP

Head and Neck Cancers

Immunotherapy in the treatment of head and neck cancers
Maura Gillison, MD, PhD

Treatment of salivary gland cancers

Boyd Gillespie, MD, MSc, FACS 

De-escalation of therapy in HPV-related oropharyngeal cancer
Ezra Cohen, MD

Keynote Lecture

AJCC updates and innovations: Hot off the press
Mahul Amin, MD

WCC Molecular Tumor Board

High throughput molecular tumor board with cases – process and outcomes: 3 year experience
Moderator: Ari VanderWalde, MD, MPH, MBioeth

Lung Cancer

Optimal treatment of stage IA lung cancer in the era of low-dose computed tomography lung cancer screening
Puneeth Iyengar, MD, PhD                

Immunotherapy in lung cancer: Breaking into a curative role?
Howard L. (Jack) West, MD

Individualization of advanced lung cancer
Leora Horn, MD

  • Mahul B. Amin, MDWest Cancer Center
    University of Tennessee Health Science Center
    Memphis, Tennessee, United States
  • Ezra Cohen, MDUniversity of California at San Diego
    San Diego, California, United States
  • Robert L. Coleman, MD, FACOG, FACSThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Jeremiah Deneve, DO, FACSWest Cancer Center
    Memphis, Tennessee, United States
  • Anthony Elias, MDUniversity of Colorado
    Denver, Colorado, United States
  • Thomas J. George, Jr, MD, FACPUniversity of Florida
    Gainesville, Florida, United States
  • M. Boyd Gillespie, MD, MSc, FACSWest Cancer Center
    University of Tennessee Health Science Center
    Memphis, Tennessee, United States
  • Maura Gillison, MD, PhDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Petros Grivas, MD, PhDCleveland Clinic
    Cleveland, Ohio, United States
  • Amit Gupta, MD, MPHCedars-Sinai Medical Center
    Los Angeles, California, United States
  • Tina Hieken, MD, FACSMayo Clinic
    Rochester, Minnesota, United States
  • Leora Horn, MDVanderbilt-Ingram Cancer Center
    Nashville, Tennessee, United States
  • Puneeth Iyengar, MD, PhDUniversity of Texas Southwestern
    Dallas, Texas, United States
  • Wells Messersmith, MD, FACPUniversity of Colorado
    Denver, Colorado, United States
  • Edith P. Mitchell, MD, FACP, FCPPThomas Jefferson University
    Philadelphia, Pennsylvania, United States
  • Daniel P. Petrylak, MDYale Cancer Center
    New Haven, Connecticut, United States
  • Lee Schwartzberg, MD, FACPWest Cancer Center
    Memphis, Tennessee, United States
  • Andrew Seidman, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Ari VanderWalde, MD, MPH, MBioeth West Cancer Center
    University of Tennessee Health Science Center
    Memphis, Tennessee, United States
  • Howard L. (Jack) West, MDSwedish Cancer Institute
    Seattle, Washington, United States

This educational activity is specifically designed to meet the needs of practicing medical oncologists, hematologists, surgeons, radiation oncologists, pathologists, nurses, and other healthcare professionals involved in the treatment of cancer.

After successful completion of this educational activity, participants should be able to:

  • Identify novel targeted and immunologic approaches to therapy for breast and ovarian cancers
  • Assess emerging targeted and immunologic therapies for genitourinary malignancies, including prostate and renal cell cancer
  • Integrate recent findings on healthcare disparities into optimal therapy selection for individual patients with cancer
  • Identify optimal therapies for patients with gastrointestinal malignancies such as carcinoid tumors, colorectal cancer, and hepatocellular carcinoma
  • Select optimal approaches to therapy for head and neck cancers, including considerations for immunotherapy
  • Describe findings from recent clinical trials evaluating target therapies and immunotherapies in lung cancer

This educational activity is supported by grants from Merck and Co, Inc. and Novartis Oncology.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Amin has disclosed that he has received payment for lectures from Genomic Health. He also received fees for participation in advisory boards and/or study participation from Cell Max, Otsuka Pharmaceuticals, and Urogen. He also disclosed pending participation on an advisory board for Precipio Lab. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ballo has disclosed that he has received consulting fees, payment for lectures, and fees for participation in advisory or review activities from Novocure. He also received support for travel to meetings from Elekta. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cohen has disclosed that he has received consulting fees from AstraZeneca; Bristol-Myers Squibb; Eisai; Human Longetivity, Inc.; Merck; and Pfizer. He received fees for participation in advisory or review activities from AstraZeneca, Bristol-Myers Squibb, Eisai, Merck, and Pfizer. He also received stock or stock options from Human Longevity, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Coleman has disclosed that he has received consulting fees from AbbVie; Debiopharma; Genmab; ImmunoGen; Merrimack; Navigant Consulting; Perthera; Vaniam Group, LLC; and Verastem. He received payment for lectures from Onc Live and Roche. He received fees for serving on a scientific advisory board from AstraZeneca; Bayer Healthcare, Inc.; Caris Life Sciences; Cerulean; Clovis Oncology; GamaMabs; Janssen; Novocure; Precision Oncology; Roche; and Tesaro. He also performed funded research for Array Bio Pharmaceuticals, AstraZeneca, Clovis Oncology, EMD Serono, Gradalis, Janssen, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dasari has disclosed that he has received research funding and fees for participation in advisory or review activities from Ipsen and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Deneve has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Elias has disclosed receipt of consulting fees from Genentech. He also disclosed receipt of research funding for clinical trials from Astellas, CytRx, Immune Design, and Innocrin. He also disclosed stock or stock options in Abbott, AbbVie, Allergan, Celgene, Gilead, Lilly, Merck, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fenton has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Fine has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fleming has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr George has disclosed that he has received consulting fees from Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gillespie has disclosed that he has consulted for Cook Medical and Omniguide. He has received consulting fees from Inspire Medical. He also received research funding from ImThera and Zelegent. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gillson has disclosed receipt of consulting fees or honorarium from Bristol-Myers Squibb and Celgene. She has also disclosed receipt of support for travel to meetings from Bristol-Myers Squibb. She also disclosed receipt of research funding to her institution for researching funding for clinical research from Amgen, AstraZeneca, Bristol-Myers Squibb, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Grivas has disclosed that he has received consulting fees and fees for participation in advisory or review activities from AstraZeneca, Biocept, Bristol-Myers Squibb, Clovis Oncology, EMD Serono, Exelixis, Genentech, and Merck & Co. He has received payment for lectures from Bristol-Myers Squibb. He also received research funding from AstraZeneca; Bayer; Genentech; Merck & Co.; Mirati; Oncogenex; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gupta has disclosed that he has received fees for participation in advisory or review activities from Exelixis. He also received stock or stock options from EDAP. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hieken has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Horn has disclosed that she has received consulting fees and fees for participation in advisory or advisory activities from AstraZeneca, AbbVie, Bristol-Myers Squibb, Genentech, and Merck. She has received support for travel to meetings from Boehringer Ingelheim. She also received research funding from AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Takeda. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Iyengar has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Robert Koch has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Messersmith has disclosed he is the local principal investigator for research funding received by the University of Colorado from Aduro, Alexo, D3 Pharma, Immunomedics, Incyte, Millennium/Takeda, OncoMed, Pfizer, and Roche/Genentech. He also disclosed receipt of fees for participation in advisory or review activities from Gilead DMSC and Purdue Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mitchell has disclosed that she has received fees for participation in advisory or review activities from Novartis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Petrylak has disclosed that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millinneum, Pfizer, Roche Laboratories, Sanofi Aventis, and Tyme Pharmaceuticals. He received research funding from Agensys, Dendreon, Eli Lilly, Johnson & Johnson, Merck, Millinneum, OncoGenex, Progenics, Roche Laboratories, and Sanofi Aventis. He also received stock or stock options from Bellicum and Tyme Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schwartzberg has disclosed that he has received consulting fees or honoraria from Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Seidman has disclosed that he has received consulting fees or honoraria from Eisai, Genentech, Novartis, and Pfizer. He has received payment for lectures from Celgene, Eisai, Genentech, Genomic Health, Novartis, and Pfizer. He has received research funding from Bayer and Novartis. He also received fees for participation in advisory or advisory activities from Eisai, Genentech, Pfizer, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shibata has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Somer has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vaena has disclosed that he has received fees for participation in advisory or review activities from AstraZeneca and Exelixis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr VanderWalde has disclosed that he has been a contracted employee for George Clinical and Vector Oncology. He has received research funding from Amgen. He also received fees for participation in advisory or advisory activities from Amgen, AstraZeneca, and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vidal has disclosed that he has received payment for lectures from AstraZeneca and Pfizer. He also received fees for participation in advisory or review activities from Eli Lilly and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Weksler has disclosed that he has received consulting fees from Intuitive Surgical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr West has disclosed that he has received consulting fees from Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Merck, PharmaMar, and Takeda. He received payment for lectures from Ariad, Bristol-Myers Squibb, and Genentech/Roche. He also received fees for participation in advisory or review activities from AstraZeneca, Bristol-Myers Squibb, and Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Elizabeth Cameron, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.